Bayyana tsarin hanyar sakamako na dopamine a cikin ADHD: abubuwan da ke cikin asibiti. (2009)

Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swanson JM.

Cibiyar Nazarin Shan Miyagun Kwayoyi ta Ƙasa, 6001 Babban Blvd, Ɗaki 5274, MSC 9581, Bethesda, MD 20892, Amurka. [email protected]

Erratum a JAMA. 2009 Oct 7; 302 (13): 1420.

Abstract

KARANTA:

Rashin hankali / raunin hankali (ADHD) - wanda aka nuna shi ta hanyar alamun rashin kulawa da tsinkaye-impulsivity – shine mafi yawancin cututtukan ƙwaƙwalwar yara waɗanda ke ci gaba da girma har zuwa girma, kuma akwai ƙarin tabbaci na rashi-dalili na rashin ƙarfi a cikin wannan matsalar.

MUTANE:

Don kimanta ɗakunan dabarun nazarin halittu wanda zai iya haifar da raguwa / motsawa ta hanyar samfurin maɓalli na kwakwalwa tafarkin sakamako na sakamako (mesoaccumbens).

ZUWA, GABATARWA, DA SABANTA:

Mun yi amfani da magungunan fitarwa na kwayoyin halitta na kwayoyin dopamine (masu karba da magunguna da kuma D (2) / D (3) a cikin 53 wadanda ba a kula da su ba tare da ADHD da kuma 44 masu sarrafa lafiya a tsakanin 2001-2009 a Laboratory National na Brookhaven.

KASHE MAYIN KASHI:

Mun auna ƙayyadadden ƙwayar magungunan radiological linkaɗa na masu amfani da kwayar halitta (DAT) ta amfani da cocaine [[11] C] da kuma masu amfani da D (2) / D (3) ta amfani da [(11) C] raclopride, Volume -1).

Sakamakon:

Ga duka ligands, taswirar ma'auni na ƙididdiga ya nuna cewa takamaiman ɗaurewa ya kasance ƙasa a cikin ADHD fiye da sarrafawa (ƙofar don mahimmancin da aka saita a P <.005) a cikin yankuna na hanyar lada ta dopamine a gefen hagu na kwakwalwa. Nazarin yanki-na sha'awa yana tabbatar da waɗannan binciken. Ma'anar (95% tazarar amincewa [CI] na ma'anar bambanci) don DAT a cikin ƙananan mahaifa don sarrafawa shine 0.71 vs 0.63 ga waɗanda ke tare da ADHD (95% CI, 0.03-0.13, P = .004) kuma a cikin tsakiyar kwakwalwa don sarrafawa ya kasance 0.16 vs 0.09 ga waɗanda ke tare da ADHD (95% CI, 0.03-0.12; P <ko = .001); don masu karɓa na D (2) / D (3), maɓallin ƙara don sarrafawa ya kasance 2.85 vs 2.68 don waɗanda ke tare da ADHD (95% CI, 0.06-0.30, P = .004); kuma a cikin tsakiyar kwakwalwa, ya kasance don sarrafawa 0.28 vs 0.18 ga waɗanda ke tare da ADHD (95% CI, 0.02-0.17, P = .01). Binciken ya kuma tabbatar da bambance-bambance a cikin hagu na hagu: ma'anar DAT don sarrafawa ita ce 0.66 vs 0.53 ga waɗanda ke tare da ADHD (95% CI, 0.04-0.22; P = .003) da ma'anar D (2) / D (3) don sarrafawa ya kasance 2.80 vs 2.47 ga waɗanda ke tare da ADHD (95% CI, 0.10-0.56; P = .005) da kuma bambance-bambance a cikin D (2) / D (3) a cikin yankin hypothalamic, tare da sarrafawar da ke da ma'anar 0.12 vs 0.05 don waɗanda ke tare da ADHD (95% CI, 0.02-0.12; P = .004). Atididdigar hankali ya haɗu da D (2) / D (3) a cikin accumbens (r = 0.35; 95% CI, 0.15-0.52; P = .001), tsakiyar tsakiya (r = 0.35; 95% CI, 0.14-0.52; P = .001), caudate (r = 0.32; 95% CI, 0.11-0.50; P = .003), da hypothalamic (r = 0.31; CI, 0.10-0.49; P = .003) kuma tare da DAT a cikin tsakiyar kwakwalwa (r = 0.37; 95% CI, 0.16-0.53; P <ko = .001).

Kammalawa:

Ragewa a alamomin synaptic dopamine da ke hade da alamu na rashin kulawa an nuna su a hanyar hanyar sakamako ta dopamine na mahalarta tare da ADHD.


Rashin Hankali/Rashin Aiki Mai Yawan Tasiri (ADHD) yana da alaƙa da alamun rashin kulawa, yawan aiki, ko rashin kuzari wanda ke haifar da rauni a fannoni daban-daban na fahimta, halayya, da kuma hulɗa da mutane. 1 Ko da yake tsawon shekaru da yawa ana tsammanin yana da matsala ta ƙuruciya da samartaka, yanzu an gane cewa yana faruwa ne a lokacin girma. An kiyasta cewa ADHD yana shafar kashi 3% zuwa 5% na yawan mutanen da ke da manyan cututtuka a Amurka, 2 wanda hakan ya sa ya zama ɗaya daga cikin cututtukan tabin hankali da suka fi yawa.

An gabatar da dalilan kwayoyin halitta da muhalli da ke haifar da dopamine mai amsawa ga ADHD. 3 Nazarin kwayoyin halitta ya gano wasu kwayoyin halitta da ke da bambancin kwayoyin halitta da ke da alaƙa da ADHD, inda aka fi maimaita su sune kwayoyin halittar dopamine guda 2 (misali, kwayoyin halittar DRD4 da DAT 1 ), 3 da nazarin muhalli sun gano muhimman abubuwan da ke haifar da haɗarin da ba na kwayoyin halitta ba (misali, shan taba a lokacin daukar ciki da matakan gubar ) waɗanda kuma za su iya shafar tsarin dopamine na kwakwalwa. 4 Shaida daga nazarin hoton kwakwalwa ta nuna cewa ana samun matsala wajen watsa kwayar halittar dopamine ta kwakwalwa a ADHD 5-9 kuma waɗannan gibin na iya zama tushen manyan alamun rashin kulawa 8 da rashin himma. 9

Akwai kuma ƙarin wayar da kan jama'a cewa marasa lafiya da ke fama da ADHD na iya samun ƙarancin lada da ƙarfafawa. 10-12 Duk da cewa an bayyana su ta hanyoyi daban-daban na bincike, wannan ƙarancin lada-ƙari yawanci ana siffanta shi da canjin hali mara kyau bayan yanayin lada da hukunci. Misali, idan aka kwatanta da yaran da ba a gano su ba, waɗanda ke fama da ADHD ba sa canza halayensu idan aka fuskanci canjin yanayin lada. 13 Hanyar dopamine ta mesoaccumbens, wacce ke fitowa daga yankin ventral tegmental (VTA) a cikin tsakiyar kwakwalwa zuwa ƙwayoyin nucleus tana da mahimmanci a cikin lada da ƙarfafawa 14 kuma an yi hasashen cewa tana da alaƙa da lada da ƙarancin ƙarfafawa da aka gani a cikin ADHD. 11 , 15 Hakika, binciken da aka yi kwanan nan na aikin magnetic resonance imaging (fMRI) ya nuna raguwar kunna ƙwayoyin nucleus accumbens tare da sarrafa lada a cikin mahalarta da ke fama da ADHD. 16-17 Duk da haka, ga iliminmu , babu wani bincike da ya auna alamun dopamine na synaptic kai tsaye a cikin yankin ƙwayoyin cuta na mutanen da ke fama da ADHD.

Dangane da wannan, mun yi hasashen rashin daidaituwa a cikin hanyar dopamine ta mesoaccumbens (wanda ya ƙunshi ƙwayoyin dopamine a cikin tsakiyar kwakwalwa da kuma hasashensu ga accumbens) a cikin ADHD. Don gwada wannan hasashe, mun kimanta samuwar dopamine D 2 / D 3 receptor (dopamine postsynaptic marker) da kuma samuwar DAT (dopamine presynaptic marker) a cikin waɗannan yankunan kwakwalwa a cikin manyan mahalarta 53 tare da ADHD (ba a taɓa yin magani ba) da kuma 44 waɗanda ba na ADHD ba ta amfani da positron emission tomography (PET) da duka [ 11 C]raclopride da [ 11 C]cocaine (D 2 / D 3 receptor da DAT radioligands bi da bi). 18 , 19

MODANE

Wanda su ka Halarta

An gudanar da hoton PET a dakin gwaje-gwaje na ƙasa na Brookhaven kuma an gudanar da ɗaukar majinyata da tantance su a Jami'ar Duke, Cibiyar Kiwon Lafiya ta Mount Sinai, da Jami'ar California, Irvine, daga 2001-2009. An sami amincewar hukumar bita ta cibiyoyi daga dukkan cibiyoyin da suka shiga. An sami izini a rubuce daga dukkan mahalarta bayan an yi musu cikakken bayani game da binciken. An biya mahalarta kuɗin shiga. Mun yi nazarin marasa lafiya 53 da ba su taɓa shan magani ba na ADHD (gami da 20 da aka bayyana a cikin rahoton da ya gabata na DAT mai tsanani da sakin dopamine 6 , 8 ) da kuma kula da lafiya 44. An ɗauki mahalarta da ke fama da ADHD daga wuraren da aka tura su zuwa shirye-shiryen ADHD a kowace cibiya.

Don rage rikicewa daga bayyanar da magungunan ƙwayoyi ko rikice-rikice, an cire mahalarta idan suna da tarihin tarihi na cin zarafin abu (ban da nicotine) ko tare da sakamako mai kyau na fitsarin fitsari, kafin ko magani na yanzu tare da magungunan psychotropic (gami da ƙarfafawa), cututtukan ƙwaƙwalwar ƙwaƙwalwa ( gano asali na I ko na II banda ADHD), cututtukan jijiyoyin jiki, yanayin kiwon lafiya wanda zai iya canza aikin ƙwaƙwalwa (watau, zuciya da jijiyoyin jini, endocrinological, oncological, ko autoimmune cututtuka), ko ciwon kai tare da asarar sani (> 30 minti). Waɗannan ƙa'idodin ƙauraran ƙaura sun ba da gudummawa ga tsawon binciken (daga 2001 zuwa 2009).

Likitoci biyu sun yi hira da marasa lafiya don tabbatar da cewa an cika sharuɗɗan ganewar asali na Bincike da Ƙididdiga na Cututtukan Hankali (Bugu na Huɗu) ( DSM-IV ), gami da kasancewar aƙalla alamun rashin kulawa 6 cikin 9 (tare da ko ba tare da alamun 6 cikin 9 masu yawan aiki ko masu saurin motsa jiki ba) kamar yadda aka tabbatar da su tare da wata hira ta hanyar amfani da gyare-gyare ga buƙatun manya na halayen ADHD. An yi amfani da sikelin tsananin yanayin Clinical Global Impressions 20 don tantance duk wani rauni. Don ganewar asali, an buƙaci mahalarta ADHD su sami aƙalla matakin matsakaicin tsanani na 4 ko sama da haka. Bugu da ƙari, an buƙaci shaida daga tarihin kowane mahalarta cewa wasu alamun ADHD sun fara kafin shekaru 7. An ɗauki magunguna daga tallace-tallace a jaridu na gida kuma sun cika sharuɗɗan keɓewa iri ɗaya amma ba sharuɗɗan haɗawa don gano ADHD ba. An cire magunguna idan sun bayyana alamun rashin kulawa ko yawan aiki wanda ke tsoma baki ga ayyukan yau da kullun. Tebur na 1 yana ba da halayen alƙaluma da na asibiti na mahalarta.

Table 1

Table 1

Yanayin Halitta da Harkokin Gudanarwa na Mahalarta

Balan Cikali

An tantance abubuwan ADHD na DSM -IV ta amfani da Ƙarfi da Rauni na Alamomin ADHD da sikelin ƙimar Halayyar Al'ada (SWAN), wanda ke amfani da sikelin tabbatacce don alamomi (1 zuwa 3) da sikelin mara kyau don akasin alamomin (−1 zuwa −3) waɗanda suka fara daga ƙasa da matsakaici zuwa sama da matsakaici. 21 Wannan yana ba mutum damar tantance cikakken kewayon aiki a cikin yankuna 2 na ADHD da aka ayyana a matsayin girma a cikin jama'a (watau hankali da aiki ko tunani) da za a tantance maimakon tsananin ilimin psychopathology da ke da alaƙa da kasancewar alamun rashin kulawa da rashin motsa jiki a cikin waɗanda ke da ADHD. Matsakaicin maki na SWANis-3 zuwa 3. Halayen psychometric na sikelin ƙimar SWAN sun fi na ma'aunin ƙimar alamun da aka yanke. An kammala kimantawa 22 akan SWAN akan mahalarta ADHD 46 da sarrafawa 38 kuma an yi amfani da su don tantance alaƙar da ke tsakanin waɗannan girma a duk mahalarta da ma'aunin PET dopamine ( Tebur 1 ).

An kuma samo shi ne sigar Conners Adult ADHD Rating Scale mai tsawo, wanda ke ba da kimantawa kan tsananin alamun ADHD akan sikelin maki 4 (ba kwata-kwata, 0; kaɗan kawai, 1; kusan, 2; da kuma sosai, 3). An bayar da maki takwas (jerin maki masu yiwuwa): A, matsalolin rashin kulawa/tunani (0-36); B, rashin aiki/rashin natsuwa (0-36); C, rashin iya motsa jiki/jin daɗi (0-36); D, matsaloli tare da ra'ayin kai (0-18); E, alamun rashin kulawa na DSM-IV (0-27); F, alamun rashin aiki na DSM-IV (0-27); G, jimlar alamun DSM-IV (0-54); da H, ma'aunin ADHD (0-36). 23 An yi amfani da wannan tsarin kimantawa sosai a wuraren asibiti da bincike kuma yana da ingantaccen tsarin factor, aminci, da inganci ( Tebur 1 ). 24

PET Scans

An yi amfani da tomograph na Siemens HR + (Siemens/CTIKnoxville, Tennessee; ƙudurin 4.5 × 4.5 × 4.5 mm cikakken faɗin rabin matsakaicin). An fara gwajin dynamic nan da nan bayan allurar 4 zuwa 10 mCi na [ 11 C]raclopride (aiki na musamman 0.5–1.5 Ci/μM a ƙarshen jefa bom) da kuma bayan allurar 4 zuwa 8 mCi na [ 11 C]cocaine (aiki na musamman >0.53 Ci/μmol a ƙarshen jefa bom) kuma an samu su na tsawon mintuna 60 kamar yadda aka bayyana a baya. 18 , 19 An sami jinin jijiya don auna yawan rashin daidaituwa [ 11 C]raclopride 18 da [ 11 C]cocaine 19 inplasma. Nazarin da aka yi a Forth, [ 11 ] an zaɓi cocaine a matsayin DAT radioligand saboda takamaiman ɗaurewar sa yana da zaɓi ga DAT (haɗin sa yana hana shi ta hanyar magunguna waɗanda ke toshe DAT amma ba ta hanyar magunguna ba, toshewar norepinephrine ko masu jigilar serotonin) 25 ; yana ba da matakan sake samarwa lokacin da aka gwada mahalarta a lokuta daban-daban 19 kuma motsin sa ya dace da ƙididdigewa a cikin jiki. 26 Bugu da ƙari, haɗawarsa abin dogaro ne sosai, wanda yake da mahimmanci lokacin gudanar da bincike mai rikitarwa kamar waɗanda aka yi a cikin wannan binciken.

Binciken Hotuna da Labari

A [11C] raclopride da [11C] hotunan cocaine sun canza zuwa siffofin girman rabo ta hanyar sarrafa yawan adadin rarraba a kowace pixel sannan kuma raba shi ta hanyar rarraba a cikin cerebellum. Don samun rabon rarraba, yankuna madauwari a hemispheres na hatsari sun samo asali a cikin jiragen 2 dake -28 mm da -36 mm daga filin jirgin sama na tsakiya. An yi amfani da yankunan karkara a lokacin da aka yi amfani da su don samun karfin da 11 C vs lokaci, wanda tare da maida hankali na mai juya baya canzawa a cikin plasma an yi amfani da shi don lissafin rarraba rarraba a cikin cerebellum, ta yin amfani da fasaha na zane-zane na tsarin sassauci.26 Bmax/Kd (rabo mai girma -1, wanda Kd da kuma Bmax suna da tasiri a cikin maɗaukakawa a gaban maɗaukakin neurotransmitter da ƙayyadadden ƙuƙwalwa) an yi amfani dashi a matsayin ma'auni na D2/D3 receptor da DAT kasancewa.26 A rabo Bmax/Kd aka auna ta wannan hanyar ana kiran shi mai yiwuwa, BPND. Har ila yau an auna shi ne mai sauyin ƙwayar cutar ƙwayar cuta (K1) a cikin striatum da cerebellum ga duka radioligands ta yin amfani da fasaha na zane-zane.26

An yi amfani da taswirar siga ta ƙididdiga 27 don tantance bambance-bambancen da ke cikin hotunan rabon rarrabawa (don [ 11 C]raclopride da [ 11 C]hocaine images) tsakanin sarrafawa da mahalarta da ke fama da ADHD ba tare da zaɓin farko na yankunan kwakwalwa na jiki ba. Don wannan dalili, an daidaita hotunan rabon rarrabawa ta hanyar amfani da samfurin Cibiyar Nazarin Jijiyoyi ta Montreal da aka bayar a cikin fakitin taswirar siga ta ƙididdiga 99 (Wellcome Trust Centre for Neuroimaging, London, England) sannan aka sassauta su da ƙwayar Gaussian isotropic 16-mm. An gudanar da gwaje-gwajen t masu zaman kansu don kwatanta bambance-bambancen da ke tsakanin ƙungiyoyi. An saita mahimmanci a P< .005 (an gyara gungu > voxels 100) kuma an lulluɓe taswirar siga ta MRI.

An tabbatar da mahimmancin da aka gano ta hanyar taswirar ƙididdiga ta hanyar amfani da nazarin yanki mai amfani da kansa ta amfani da samfura daga bayanan Talairach Daemon. 28 Hoto na 1 yana nuna wurin yankin da ake amfani da shi don wannan binciken. An tantance bambance-bambancen da ke cikin mai karɓar D 2 /D 3 da samuwar DAT tare da gwaje-gwajen t masu zaman kansu (2 masu wutsiya).

Figure 1

Figure 1

Yankuna masu ban sha'awa da ake amfani dasu don cire D2/D3 Ka'idojin karbar maganin juyi da ƙwayar matsala

An yi amfani da alaƙar samfurin Pearson-lokacin don tantance alaƙar da ke tsakanin masu karɓar DAT da D 2 /D 3 da kuma girma 2 na ma'aunin ƙimar SWAN (hankali da aiki ko nuna haske).

Ma'anar bambanci mai mahimmanci ga ma'aunin sakamako na 1 shine cewa kwatancen taswirar ƙididdiga na DAT da hotunan D 2 /D 3 dole ne su kasance masu mahimmanci a P< .005 (an gyara gungu > voxels 100) kuma binciken yanki dole ne a tabbatar da shi ta hanyar yankin da aka zana daban-daban na sha'awa 2 ; kwatancen waɗannan matakan tabbatarwa dole ne su kasance masu mahimmanci a P< .05 3 ; nazarin alaƙa dole ne ya zama mai mahimmanci a P< .006, wanda aka zaɓa don kiyaye matakin mahimmanci na P< .05 gabaɗaya bisa ga gyaran Bonferroni don yankuna 4 da ma'aunin asibiti 2 (hankali da aiki ko tunani). Kunshin ƙididdiga da aka yi amfani da shi shine Statview, sigar 5.0.1 (Abacus Concepts, Berkeley, California).

Lissafin girman samfurin wannan binciken ya dogara ne akan bincikenmu na farko (tare da ƙananan girman samfura) akan masu karɓar DAT 6 da D 2 /D 3 , 8 wanda ya nuna bambanci a cikin caudate tsakanin ƙungiyoyi a girman sakamako (rabo tsakanin matsakaicin bambanci da daidaitaccen karkacewa) tsakanin 0.65 da 0.80. Ga irin waɗannan girman tasirin, don cimma ƙarfin akalla 80% ta amfani da gwajin samfuran masu zaman kansu t tare da matakin mahimmanci na .05 (gefe 2), muna buƙatar ɗaukar aƙalla mahalarta 40 a kowace rukuni. Girman samfurin ƙarshe na 53 a cikin ADHD da 44 a cikin ƙungiyoyin sarrafawa sun ba da damar gano matsakaicin bambance-bambancen da aka kiyasta tare da iko tsakanin 88% da 97% ta hanyar gwajin samfuran masu zaman kansu t a matakin mahimmanci na .05 (gefe 2).

Sakamakon

Dopamine D2/D3 Masu karɓa

Binciken taswirar ƙididdiga na girman rabon rarrabawa [ 11 C]raclopride ya nuna rukuni 1 tare da ƙarancin samuwar D2 /D3 a cikin mahalarta ADHD fiye da sarrafawa a cikin yankin hagu. Wannan rukuni ya haɗa da yankunan kwakwalwa na hanyar lada ta dopamine - ventral caudate, accumbens, da tsakiyar kwakwalwa, da kuma yankin hypothalamic ( Hoto na 2 da eTable da ake samu a http://www.jama.com ). An tabbatar da waɗannan binciken ta hanyar yankin da aka zana daban-daban, wanda kuma ya nuna bambance-bambancen sarrafa ADHD a cikin hagu accumbens, midbrain, caudate, da kuma a cikin yankunan hypothalamic ( Tebur na 2 ). Babu yankuna da suka fi girma a cikin mahalarta ADHD fiye da a cikin sarrafawa. Sabanin haka, ma'aunin K1 na [ 11 C]raclopride (jigilar radioligand daga jini zuwa kyallen takarda) bai bambanta ko dai a cikin caudate na hagu ba tare da ƙungiyoyin biyu suna da matsakaicin 0.11 (tazara ta amincewa ta 95% [CI], −0.01 zuwa 0.006 matsakaicin bambanci) ko kuma a yankin accumbens na hagu tare da sarrafawa yana da matsakaicin 0.12 idan aka kwatanta da matsakaicin 0.11 ga waɗanda ke da ADHD (95% CI, −0.01 zuwa 0.005).

Figure 2

Figure 2

Yankuna a cikin Brain a Wace Matakan Matsalar da ke Ƙasa a cikin Masu Mahalarta tare da ADHD Fiye da Gudanarwa

Table 2

Table 2

Matakan Matsalar D2/D3 Mai saukewa da ƙwarewar matsalaa

Ma'aikata masu tasowa

Binciken taswirar ƙididdiga na girman rabon rarraba cocaine [ 11C ] ya nuna wani rukuni a wuri ɗaya kamar yadda aka nuna a cikin hotunan [ 11C ]raclopride. Wannan rukuni ya haɗa da yankunan hagu na ventral caudate, accumbal, midbrain, da hypothalamic, kuma a cikin waɗannan yankuna matsakaicin samuwar DAT ya yi ƙasa da na mahalarta ADHD fiye da sarrafawa ( Hoto na 2 da eTable ). Babu yankuna da suka fi girma a cikin mahalarta ADHD fiye da sarrafawa. Yankin da aka zana mai zaman kansa ya tabbatar da ƙarancin samuwar DAT a cikin accumbens na hagu, midbrain, da caudate tsakanin mahalarta da ke da ADHD fiye da tsakanin sarrafawa, amma raguwar yankin hypothalamic na hagu ba ta bambanta sosai ba ( Tebur 2 ). Matsakaicin (95% CI don matsakaicin bambanci) na ma'aunin K1 na [ 11C ]hocaine bai bambanta a cikin caudate na hagu da 0.49 tsakanin sarrafawa idan aka kwatanta da 0.48 tsakanin waɗanda ke da ADHD (95% CI, −0.05 zuwa 0.03) ko a yankin accumbens na hagu tare da bambancin 0.49 vs 0.51 tsakanin waɗanda ke da ADHD (95% CI, −0.02 zuwa 0.07).

Daidaitawa tare da ADHD Symptoms Dimensions

Girman da hankali (daga SWAN) an haɗu da kyau tare da D2/D3 samfurin karɓa a cikin ƙananan ƙananan yanki (r= 0.35; 95% CI, 0.15-0.52; P=.001), hagu na tsakiya (r = 0.35; 95% CI, 0.14-0.52; P = .001), hagu na hagu (r = 0.32; 95% CI, 0.11-0.50; P=.003), kuma ya bar yankin hypothalamic (r= 0.31; 95% CI, 0.10-0.49; P=.003) da kuma DAT samuwa a cikin hagu na tsakiya hagu (r = 0.37; CI, 0.16, 0.53; P<.001; Figure 3). Saboda yawan karuwar SWAN ya nuna yawan bayyanar cututtuka tare da sikelin mai kyau (daga 1 zuwa 3) da kuma akasin bayyanar cututtuka tare da matakan ƙananan (daga -1 zuwa -3) haɓakar rashin daidaituwa ya nuna cewa ƙananan tsarin kwayoyin dopamine, mafi girma da alamun rashin kulawa . Babu wani haɗin tare da girman aikin ko nunawa ya kasance muhimmi.

Figure 3

Figure 3

Rikicin Rikici tsakanin Dopamine D2/D3 Mai saukewa da ƙwarewar ƙwarewa yana samuwa da ƙira a kan hankali

COMMENT

Binciken da ya yi ya bayar da shaida kan yadda aka yi hasashen cewa akwai cikas a cikin hanyar dopamine ta mesoaccumbens a cikin ADHD. Tare da hoton PET, an rubuta ƙarancin masu karɓar D2 / D3 da kuma samuwar DAT a cikin waɗanda ke da ADHD fiye da ƙungiyar kulawa a cikin manyan yankuna 2 na kwakwalwa don lada da kwarin gwiwa (accumbens da midbrain). 29 Hakanan yana tabbatar da katsewar alamun dopamine na synaptic a cikin caudate a cikin manya tare da ADHD kuma yana ba da shaida ta farko cewa hypothalamus na iya shafar.

Kasa da al'ada D2 / D3 receptor da DAT samuwa a yankunan accumbens da midbrain suna goyon bayan hasashen raunin hanyar lada ta dopamine a cikin ADHD . 30 Saboda ba a auna ma'aunin lada mai kyau ba, za mu iya yanke hukunci ne kawai cewa raunin hanyar lada ta dopamine na iya zama tushen shaidar asibiti na martani mara kyau ga lada a cikin ADHD. Rashin lada a cikin ADHD yana da alaƙa da gazawar jinkirta gamsuwa, rashin amsawa ga jadawalin ƙarfafawa na ɗan lokaci, da fifiko ga ƙananan lada nan take fiye da manyan lada masu jinkiri. 31 Daidai da wannan muhimmin fasalin asibiti na ADHD syndrome, wani bincike na fMRI na baya-bayan nan ya ba da rahoton raguwar kunnawa na ventral striatum (inda akwai nucleus accumbens) don lada nan take da jinkiri a cikin manyan mahalarta tare da ADHD idan aka kwatanta da sarrafawa. 17

A cikin bincikenmu, ma'aunin masu karɓar D 2 /D 3 a cikin accumbens sun kasance da alaƙa da girman hankali, wanda zai haifar da hanyar lada ta dopamine a cikin alamun rashin kulawa a cikin ADHD. Wannan zai iya ba da bayani game da dalilin da yasa ƙarancin kulawa a cikin mutanen da ke da ADHD ya fi bayyana a cikin ayyukan da ake ɗauka marasa daɗi, masu maimaitawa, kuma ba su da ban sha'awa (watau, ayyuka ko ayyukan da ba su da lada a zahiri). 32 A ƙarshe, saboda ƙarancin adadin masu karɓar dopamine D 2 /D 3 a cikin accumbens na tsakiya an danganta su da babban haɗarin shan miyagun ƙwayoyi, 33 aikin nan gaba ya kamata ya tantance ko ƙarancin samuwar masu karɓar D 2 /D 3 fiye da na al'ada a cikin yankin accumbens a cikin ADHD shine babban raunin da ake samu ga shan miyagun ƙwayoyi a cikin wannan yawan jama'a. 34

Rage yawan masu karɓar D2 / D3 da kuma samuwar DAT a cikin kwakwalwa ta tsakiya, wanda ya ƙunshi yawancin ƙwayoyin dopamine a cikin kwakwalwa, ya yi daidai da binciken da aka yi a baya game da yara da matasa masu ADHD waɗanda ke nuna rashin daidaituwar kwakwalwa ta tsakiya. 5 , 35 Wannan na iya haifar da raguwar sakin dopamine da aka ruwaito a cikin manya masu ADHD 8 saboda harba ƙwayoyin dopamine a cikin kwakwalwa ta tsakiya yana da alhakin sakin dopamine a cikin striatum. Bugu da ƙari, mummunan alaƙa tsakanin alamun dopamine a cikin kwakwalwa ta tsakiya da girman hankali (masu karɓar DAT da D 2 ) yana nuna cewa rashin siginar daga ƙwayoyin dopamine na iya taimakawa wajen tsananin alamun rashin kulawa a cikin ADHD.

Ƙananan fiye da al'ada D2/D3 masu karɓa da kuma DAT samuwa a cikin ADHD a cikin caudate an kuma nuna su. Nazarin karatun farko ya bayar da rahoton karamin kundin littafin36-40 da kuma aikin caudate a yayin kunnawa41,42 a cikin ADHD mahalarta kwatanta da controls. Ya bambanta, binciken DAT a striatum (ciki har da caudate) sun kasance ba daidai ba a nazarin mahalarta tare da ADHD da hukumomi, tare da wasu takardun karatu masu ɗaukaka,43 wasu ƙananan,6 kuma wasu ba bambance-bambance.44 Dalilin (s) don rashin daidaituwa an bayyana su a inda6 kuma zai iya nuna bambancin ra'ayoyin masu radiyo, hanyoyin da aka yi amfani da su (masu radiyo, PET da sau ɗaya daga cikin halayen photon da aka tsara), bambance-bambance a cikin halaye marasa lafiya (ciki har da tarihin shan magani, comorbidities, da shekarun mahalarta), da samfurori masu yawa, waɗanda suka bambanta daga 6 zuwa 53 (a wannan binciken). Wadannan binciken sun bambanta da wadanda aka ruwaito su a cikin matasa tare da ADHD, wanda ya nuna mafi girma D2/D3 samuwa mai karɓa a cikin hagu na striatum (ciki har da caudate) fiye da matasa, wanda aka fassara don nuna rashin fahimtar rashin zama cikin wadannan masu karɓar ragamar kwayoyin halitta.7 A cikin waɗannan matasan da ke ADHD, yawancin ƙarawa a cikin D2/D3 an samu samuwa a cikin marasa lafiya wadanda a lokacin haihuwar suna da ƙananan jinin jini, wanda aka fassara don nuna tasirin sakamakon mummunar matsalar da ake ciki a kan aikin kwakwalwa na kwayoyin halitta.9

Binciken farko da aka ruwaito a nan game da ƙarancin dopamine D2 / D3 masu karɓar rakiyar da aka samu a yankin hypothalamic na mahalarta ADHD abin sha'awa ne domin idan aka maimaita shi, zai iya samar da tushen jijiyoyi don yawan kamuwa da cutar ADHD tare da alamu da alamu waɗanda ke nuna alamun cututtukan hypothalamic 45 kamar matsalolin barci, kiba 46 ko kiba, 47 da kuma martani marasa kyau ga damuwa. 48 Masu karɓar dopamine D2 masu karɓar rakiyar hypothalamic da yawa , 49 amma ƙarancin ƙudurin sarari na gwajin PET bai ba da damar gano inda bambance-bambancen da ke tsakanin ƙungiyoyin suka faru ba . Abin da ya dace da rawar da hypothalamus ke takawa a ADHD shine haɗin maye gurbi a cikin kwayar halittar melanocortin-4-receptor ( MC4R ), wanda aka bayyana a cikin ƙwayoyin hypothalamic da yawa waɗanda ke haifar da kiba, tare da ADHD. 50

Bincikenmu na alaƙar hanyar dopamine ta mesoaccumbens tare da alamun rashin kulawa na ADHD na iya zama da mahimmanci a asibiti. Wannan hanyar tana taka muhimmiyar rawa a cikin ƙarfafawa-ƙarfafawa da kuma ƙungiyoyin lada na ilmantarwa, 51 kuma shigarta cikin ADHD tana tallafawa amfani da hanyoyin shiga tsakani don haɓaka daidaiton ayyukan makaranta da na aiki don inganta aiki. An nuna cewa duka hanyoyin shiga tsakani na ƙarfafawa da kuma kula da gaggawa suna inganta aiki ga marasa lafiya da ADHD. 52 Hakanan an nuna cewa magungunan motsa jiki suna ƙara yawan aiki na fahimta (ƙarfafawa, sha'awa) gwargwadon ƙaruwar dopamine da miyagun ƙwayoyi ke haifarwa a cikin striatum. 53

gazawar

[ 11 C] Matakan Raclopride suna tasiri ta hanyar dopamine na extracellular (mafi girman dopamine na extracellular, ƙarancin ɗaurewar [ 11 C]raclopride zuwa masu karɓar D2 / D 3 ), don haka ƙarancin ɗaurewa na iya nuna ƙarancin matakan masu karɓar D2 / D 3 ko ƙaruwar sakin dopamine. 54 Duk da haka, na ƙarshen ba zai yiwu ba tunda mun riga mun bayar da rahoton cewa sakin dopamine a cikin ƙaramin rukuni na mahalarta ADHD ɗinmu ya yi ƙasa da na sarrafawa. 8 Hakanan kodayake [ 11 C] ɗaurewar cocaine zuwa DATs ba ta da tasiri sosai ta hanyar gasa da dopamine na endogenous, 55 samuwar DAT ba wai kawai yana nuna yawan tashoshin dopamine ba har ma da sautin dopamine na synaptic, saboda DAT yana ƙaruwa lokacin da dopamine na synaptic ya yi yawa kuma yana raguwa lokacin da dopamine ya yi ƙasa. 56 Don haka ƙarancin samuwar DAT zai iya nuna ƙarancin tashoshin dopamine ko raguwar bayyanar DAT a kowace tashar dopamine.

Ƙanƙantar kusancin [ 11 C]raclopride da [ 11 C]hocaine ga abubuwan da suka sa suka fi dacewa da auna yankuna masu yawan D2 / D3 receptor ko DAT country (watau caudate, putamen, da accumbens) kuma ba su da saurin kamuwa da yankuna masu ƙarancin matakai kamar hypothalamus da midbrain. Duk da haka, duk da wannan iyakancewa, an nuna manyan bambance-bambance a yankuna na ƙarshe tsakanin sarrafawa da mahalarta tare da ADHD.

Wani binciken sauran binciken shi ne cewa ba a aiwatar da matakan sakamako ba. Sabili da haka, zamu iya nuna cewa ragewa a cikin alamar dopamin a cikin yankin accumbens na iya haifar da lalacewar sakamakon da aka ruwaito a marasa lafiya tare da ADHD.

Ba a sami hotunan MRI na siffofi ba, don haka ko bambance-bambancen girma a cikin striatum a cikin waɗanda ke da ADHD waɗanda za su iya ba da amsa ga waɗannan binciken ba za a iya tantance su ba tunda an ba da rahoton bambance-bambancen girma a cikin striatum a cikin ADHD. 36 - 40 Duk da haka, cewa babu bambance-bambancen rukuni a cikin ma'aunin K1 ( jigilar rediyon rediyo daga plasma zuwa kyallen takarda) a cikin striatum, wanda kuma canje-canjen girma zai shafi, yana nuna cewa waɗannan binciken suna nuna raguwar samuwar masu karɓar DAT da D 2 / D 3 maimakon raguwar tasirin ƙarar da ke biyo baya ga wani ɓangare na tasirin ƙara.

Alaƙa tsakanin haske ko rashin kuzari da kuma ma'aunin PET dopamine ba su da mahimmanci, wanda zai iya nuna cewa maki sun yi ƙasa sosai don haka rashin jin daɗin lura da irin wannan alaƙar. A madadin haka, yana iya nuna shigar yankunan gaba cikin rashin kuzari, 57 wanda ba za a iya auna shi da PET radioligands na yanzu ba; D 2 /D 3 masu karɓa da matakan DAT a yankunan gaba suna da ƙasa sosai.

Kodayake binciken da aka gano a cikin wannan binciken an ƙuntata ga hagu na hagu, ikon ƙididdiga mai yawa ya iya taimakawa wajen rashin muhimmancin ADHD-al'ada a cikin ƙananan ƙwayoyin kwakwalwa. Bugu da ƙari kuma, saboda rashin fahimtar rashin fahimta da rashin sani, babu cikakkiyar shaida a cikin wallafe-wallafen don tallafawa lalacewa don sakamako, dole ne a fassara fassarar lalacewa a matsayin mahimmanci da kuma bukatar buƙata.

Wannan binciken ba a farko an tsara su ba don kimanta ayyukan dopamin hypothalamic a ADHD. Saboda haka, wannan binciken shine na farko da kuma bukatar buƙata. Bugu da ƙari, nazarin binciken da za a yi a gaba don tsara ka'idar maganin hypothalamic a cikin ADHD da mahimmancin ƙwarewa ya kamata ya tantance alamun barci kuma bai kamata ya ƙyale mahalarta ba, kamar yadda ya faru don nazarin na yanzu.

A ƙarshe, waɗannan binciken sun nuna raguwar alamun dopamine synaptic a cikin hanyar lada ta dopamine a tsakiyar kwakwalwa da kuma haɗa yankin mahalarta tare da ADHD waɗanda ke da alaƙa da ma'aunin kulawa. Hakanan yana ba da shaidar farko ta shiga cikin hypothalamic a cikin ADHD (ƙasa da yadda aka saba samun masu karɓar D2 / D3 ).

Karin kayan

e tebur

Acknowledgments

Kuɗi/Tallafi: An gudanar da wannan binciken ne a Brookhaven National Laboratory (BNL) kuma an tallafa masa ta hanyar tallafin MH66961-02 daga Shirin Bincike na Cikin Gida na Cibiyoyin Lafiya na Ƙasa (NIH), Cibiyar Lafiyar Hankali ta Ƙasa da tallafin kayayyakin more rayuwa daga Ma'aikatar Makamashi.

Matsayin Mai Tallafawa: Hukumomin bayar da tallafi ba su shiga cikin tsara da gudanar da binciken ba; tattarawa, gudanarwa, nazari, da fassara bayanan; da kuma shiri, bita, ko amincewa da rubutun.

Bayanan kalmomi

Gudummawar Marubuci: Dr. Volkow yana da cikakken damar shiga dukkan bayanan da ke cikin binciken kuma yana ɗaukar alhakin sahihancin bayanan da kuma daidaiton nazarin bayanan.

Tsarin nazari da ƙira: Volkow, Wang, Wigal, Newcorn, Swanson.

Samun bayanai: Wang, Kollins, Wigal, Newcorn, Telang, Fowler, Pradhan.

Bincike da fassarar bayanai: Volkow, Wang, Kollins, Wigal, Newcorn, Zhu, Logan, Ma, Wong, Swanson.

Tsarin rubutun: Volkow, Wang, Fowler.

Muhimmin gyara na rubutun don muhimman abubuwan ilimi: Volkow, Wang, Kollins, Wigal, Newcorn, Telang, Zhu, Logan, Ma, Pradhan, Wong, Swanson.

Nazarin ƙididdiga: Zhu, Wong, Swanson.

An sami tallafi: Volkow, Wang, da Newcorn.

Tallafin gudanarwa, fasaha, ko kayan aiki: Wang, Kollins, Wigal, Telang, Fowler, Ma, Swanson.

Kula da karatu: Wang, Kollins, Wigal, da Fowler.

Bayanin Kuɗi: Dr. Kollins ya ba da rahoton samun tallafin bincike, kuɗin ba da shawara, ko duka biyun daga waɗannan majiyoyi: Addrenex Pharmaceuticals, Otsuka Pharmaceuticals, Shire Pharmaceuticals, NIDA, NIMH, NINDS, NIEHS, EPA. Dr. Newcorn ya ba da rahoton cewa ya sami tallafin bincike daga Eli Lilly da Ortho-McNeil Janssen, yana aiki a matsayin mai ba da shawara, mai ba da shawara, ko duka biyun ga Astra Zeneca, BioBehavioral Diagnostics, Eli Lilly, Novartis, Ortho-McNeil Janssen, da Shire kuma a matsayin mai magana da yawun Ortho-McNeil Janssen. Dr. Swanson ya ba da rahoton samun tallafi daga Alza, Richwood, Shire, Celgene, Novartis, Celltech, Gliatech, Cephalon, Watson, CIBA, Janssen, da McNeil; ya kasance a cikin kwamitin ba da shawara na Alza, Richwood, Shire, Celgene, Novartis, Celltech, UCB, Gliatech, Cephalon, McNeil, da Eli Lilly; ya kasance a ofisoshin masu magana na Alza, Shire, Novartis, Cellthech, UCB, Cephalon, CIBA, Janssen, da McNeil; kuma ya tuntuɓi Alza, Richwood, Shire, Clegene, Novarits, Celltech, UCB, Gliatech, Cephalon, Watson, CIBA, Jansen, McNeil da Eli Lilly. Dr. Wigal ya ba da rahoton samun tallafi daga Eli Lilly, McNeil, Novartis, da Shire. Babu wani rahoton kuɗi da aka bayar.

Ƙarin bayani: Ana samun eTable a http://www.jama.com.

Ƙarin Gudummawa: Muna gode wa ma'aikatan BNL masu zuwa: Donald Warner don ayyukan PET; David Schlyer da Michael Schueller don ayyukan cyclotron; Pauline Carter, Millard Jayne, da Barbara Hubbard don kula da jinya; Payton King don nazarin plasma; da Lisa Muench, Youwen Xu, da Colleen Shea don shirya radiotracer; da Karen Appelskog-Torres don daidaita ka'idoji. Muna kuma gode wa ma'aikatan Duke Joseph English da Allan Chrisman don ɗaukar ma'aikata da kimantawa; da kuma ma'aikaciyar NIH Linda Thomas don taimakon edita. Muna kuma gode wa mutanen da suka yi aikin sa kai don waɗannan nazarin. Babu ɗaya daga cikin marubutan ko mutanen da aka amince da su da aka biya diyya don gudummawar da suka bayar banda albashinsu.

References

1. Ƙungiyoyin Kula da Harkokin Kasuwancin Lafiya na Ƙungiyar Kula da Lafiya. J Am Acad Child Ado Psychiatry. 2000.39(2): 182-193. [PubMed]
2. Dopheide JA, Pliszka SR. Raunin hankali-rashin tsaka-tsaki: sabuntawa. Pharmacotherapy. 2009.29(6): 656-679. [PubMed]
3. Swanson JM, Kinsbourne M, Nigg J, et al. Ƙananan ilimin binciken ilimin likita na rashin hankali / cututtuka: kwakwalwar kwakwalwa, kwayoyin kwayoyin halitta da abubuwan muhalli da kuma maganin dopamine. Neuropsychol Rev. 2007.17(1): 39-59. [PubMed]
4. Braun JM, Kahn RS, Froehlich T, Auinger P, Lanphear BP. Bayani ga cututtuka na muhalli da rashin kulawa da cututtuka na kasawa a cikin yara na Amurka. Game da Harkokin Lafiya. 2006.114(12): 1904-1909. [PMC free article] [PubMed]
5. Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Cohen RM. Cibiyar kwakwalwa ta tsakiya (18F) DOPA a cikin yara tare da rashin kulawar rashin lafiya. Am J Zuciyar. 1999.156(8): 1209-1215. [PubMed]
6. Volkow ND, Wang GJ, Newcorn J, et al. Brain dopamine yada matakai a cikin magani da miyagun ƙwayoyi marasa lafiya da ADHD. Neuroimage. 2007.34(3): 1182-1190. [PubMed]
7. Lou HC, Rosa P, Pryds O, et al. ADHD: Ƙara yawan haɓaka mai karfin dopamine wanda ya danganta da gazawar hankali da ƙananan jinin jini. Dev Med Yaro Neurol. 2004.46(3): 179-183. [PubMed]
8. Volkow ND, Wang GJ, Newcorn J, et al. Halin da ake ciki a cikin kwayar cutar dopamine a cikin kullun da kuma shaida na farko game da cin zarafi a cikin tsofaffi tare da rashin kulawa da rashin tausayi. Arch Gen dabbai. 2007.64(8): 932-940. [PubMed]
9. Rosa Neto P, Lou H, Cumming P, Pryds O, Gjedde A. Methylphenidate-evoked yiwuwar na extracellular dopamine a kwakwalwa na matasa da haihuwa ba tare da haihuwa. Ann NY Acad Sci. 2002.965: 434-439. [PubMed]
10. Luman M, Oosterlaan J, Sergeant JA. Halin tasiri na ƙarfafawa akan AD / HD. Clin Psychol Rev. 2005.25(2): 183-213. [PubMed]
11. Johansen EB, Killeen PR, Russell VA, et al. Tushen ƙarfin ƙarfafawa a cikin ADHD. Behav Brain Funct. 2009.5: 7. [PMC free article] [PubMed]
12. Haenlein M, Caul WF. Hanyar rashin gazawar rashin lafiya tare da hyperactivity. J Am Acad Child Ado Psychiatry. 1987.26(3): 356-362. [PubMed]
13. Kollins SH, Lane SD, Shapiro SK. Tambayar gwajin gwaji na yara. Psychol Rec. 1997.47(1): 25-44.
14. Mai hikima RA. Ƙirgin alamar baƙi. Neuron. 2002.36(2): 229-240. [PubMed]
15. Sonuga-Barke EJ. Ƙarar hanzari na ƙwayar cuta / rashin lafiya. Biol Sutchiatry. 2005.57(11): 1231-1238. [PubMed]
16. Ströhle A, Stoy M, Wrase J, et al. Ra'ayin sakamako da kuma sakamakon da aka samu a cikin maza da yawa tare da matsalar kulawa da rashin tausayi / hyperactivity. Neuroimage. 2008.39(3): 966-972. [PubMed]
17. Plichta MM, Vasic N, Wolf RC, et al. Neural hyporesponsiveness da hyperresponsiveness a lokacin nan da nan kuma jinkirta lada aiki a cikin girma da hankali-deficit / hyperactivity cuta. Biol Sutchiatry. 2009.65(1): 7-14. [PubMed]
18. Volkow ND, Fowler JS, Wang GJ, et al. Reproducibility of matakan maimaita carbon-11-raclopride dauri a cikin kwakwalwa na mutum. J Nucl Med. 1993.34(4): 609-613. [PubMed]
19. Fowler JS, Volkow ND, Wolf AP, et al. Cikin taswirar cocaine daura shafuka a kwakwalwar mutum da kwakwalwa a vivo. Synapse. 1989.4(4): 371-377. [PubMed]
20. Guy W. Clinical Global Impression (CGI) sikelin. A cikin: Rush AJ, Na farko MB, Blacker D, masu gyara. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Publishing; 2000.
21. Swanson JM, Deutsch C, Cantwell D, et al. Cutar da cututtuka da cututtukan hankali. Clin Neurosci Res. 2001.1: 207-216.
22. Young DJ, Levy F, Martin NC, Hay DA. Ra'ayin rashin kulawa da rashin tausayi: Ra'idar Rasch na SWAN rating scale [da aka buga a kan layi May 20, 2009] Yaron Dan Tsibi Hum Dev. Doi: 10.1007 / s10578-009-0143-z. [Cross Ref]
23. Conners CK. Sakamakon ƙididdiga a cikin rashin hankali / rashin daidaituwa / hyperactivity cuta. J Jara Samun zuciya. 1998.59(samar da 7): 24-30. [PubMed]
24. Conners CK, Erhardt D, Sparrow E. Adult ADHD Rating Scales: Manual Manual. North Tonawanda, NY: Multi-Health Systems Inc.; 1999.
25. Volkow ND, Fowler JS, Logan J, et al. Carbon-11-cocaine daura idan aka kwatanta da subpharmacological da pharmacological doses. J Nucl Med. 1995.36(7): 1289-1297. [PubMed]
26. Logan J, Fowler JS, Volkow ND, et al. Zane-zane na zane-zane na radioligand mai ɗaukar nauyi daga ma'aunin lokaci-aiki da ake amfani da su [N-11C-methyl] - (-) - nazarin cocaine PET a cikin abubuwan da suka shafi mutum. J Cereb Blood Flow Flow. 1990.10(5): 740-747. [PubMed]
27. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Taswirar lissafi na lissafi a cikin hotunan aiki. Hum Brain Mapp. 1995.2: 189-210.
28. Lancaster JL, Woldorff MG, Parsons LM, et al. Ɗaukaka takardun tatsuniya ta atomatik don taswirar kwakwalwar kwakwalwar aiki. Hum Brain Mapp. 2000.10(3): 120-131. [PubMed]
29. Mai hikima RA, Rompre PP. Brain dopamine da sakamako. Annu Rev Psychol. 1989.40: 191-225. [PubMed]
30. Sonuga-Barke EJ. Hanyar dual hanya na AD / HD. Neurosci Biobehav Rev. 2003.27(7): 593-604. [PubMed]
31. Tripp G, Wickens JR. Cutar da zazzagewa ta kasa. J Child Psychol Psychiatry. 2008.49(7): 691-704. [PubMed]
32. Barkley RA. Ra'ayin rashin lafiya na rashin lafiya: Gargaxi don ganewa da jiyya. New York, NY: The Guilford Press; 1990.
33. Dalley JW, Fryer TD, Brichard L, et al. Mahimmancin masu karɓar D2 / 3 masu hangen nesa sun hango burbushin impulsivity da haɓakar cocaine. Science. 2007.315(5816): 1267-1270. [PMC free article] [PubMed]
34. Elkins IJ, McGue M, Iacono WG. Hanyoyin da ake iya haifar da rashin hankali-rashin raguwa / cututtuka, rikici, da jima'i game da yin amfani da magunguna da kuma zalunci. Arch Gen dabbai. 2007.64(10): 1145-1152. [PubMed]
35. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Rage tsakiya na tsakiya na kwayar hana daukar kwayar cutar a cikin maza da mata tare da ƙwayar hankali / rashin lafiya. Biol Sutchiatry. 2005.57(3): 229-238. [PubMed]
36. Castellanos FX, Giedd JN, Marsh WL, et al. Hanyoyin kwakwalwa na kwakwalwa na kwakwalwa kamar yadda ya kamata a hankali. Arch Gen dabbai. 1996.53(7): 607-616. [PubMed]
37. Filipek PA, Semrud-Clikeman M, Steingard RJ, Renshaw PF, Kennedy DN, Biederman J. Volumetric MRI kwatanta kwatanta batutuwa da ke da hankali ga rashin kulawa da cututtuka tare da kulawar al'ada. Ma'anar ilimin halitta. 1997.48(3): 589-601. [PubMed]
38. Castellanos FX, Giedd JN, Berquin PC, et al. Hanyoyin kwakwalwa na kwakwalwa ta fuskar kwakwalwa a cikin 'yan mata da rashin kulawa da rashin tausayi / rashin tausayi. Arch Gen dabbai. 2001.58(3): 289-295. [PubMed]
39. Lopez-Larson M, Michael ES, Terry JE, et al. Ƙananan bambance-bambance a tsakanin matasa tare da rashin kulawa da rashin tausayi / rashin tausayi idan aka kwatanta da wadanda ke fama da rashin lafiya tare da kuma ba tare da kulawa da rashin lafiya / kulawa. J Child Adocc Psychopharmacol. 2009.19(1): 31-39. [PMC free article] [PubMed]
40. Qiu A, Crocetti D, Adler M, et al. Basal ganglia girma da kuma siffar a cikin yara tare da hankali gaza hyperactivity cuta. Am J Zuciyar. 2009.166 (1): 74-82. [PMC free article] [PubMed]
41. Vaidya CJ, Bunge SA, Dudukovic NM, Zalecki CA, Elliott GR, Gabrieli JD. Nada ƙananan ƙananan ƙwayoyin mahimmancin kulawa a cikin yara ADHD. Am J Zuciyar. 2005.162(9): 1605-1613. [PubMed]
42. Booth JR, Burman DD, Meyer JR, et al. Ƙananan lalacewa a cikin kwakwalwa na kwakwalwa don maganin amsawa maimakon ga gani mai hankali a hankali a cikin rashin kulawar cututtuka (ADHD) J Child Psychol Psychiatry. 2005.46(1): 94-111. [PubMed]
43. Spencer TJ, Biederman J, Madras BK, et al. Ƙarin shaida na daukar kwayar cutar dopamine ta hanyar dysregulation a ADHD: PET mai sarrafawa akan nazarin binciken yin amfani da mai amfani. Biol Sutchiatry. 2007.62(9): 1059-1061. [PMC free article] [PubMed]
44. van Dyck CH, Quinlan DM, Cretella LM, et al. Rikicin dopamine wanda ba a yalwace shi ba samuwa a cikin rashin kulawa da rashin hankali ga rashin lafiya. Am J Zuciyar. 2002.159(2): 309-312. [PubMed]
45. Cortese S, Konofal E, Lecendreux M. Tsira da kuma ciyar da hali a ADHD. Matsanancin Rayuwa. 2008.71(5): 770-775. [PubMed]
46. Cortese S, Konofal E, Yateman N, Mouren MC, Lecendreux M. Barci da farkawa a cikin yara da rashin hankali da rashin tausayi. Barci. 2006.29(4): 504-511. [PubMed]
47. Waring ME, Lapane KL. Nau'i a cikin yara da matasa game da matsalar kulawa da rashin tausayi / damuwa. Pediatrics. 2008.122(1): e1-e6. [PubMed]
48. King JA, Barkley RA, Barrett S. Raunin hankali na rashin lafiya da kuma maganin damuwa. Biol Sutchiatry. 1998.44(1): 72-74. [PubMed]
49. Gurevich EV, Joyce JN. Rarrabaccen mai karɓar dopodin D3 wanda yake bayyana ƙananan ƙwararru a cikin ɗan adam. Neuropsychopharmacology. 1999.20(1): 60-80. [PubMed]
50. Agranat-Meged A, Ghanadri Y, Eisenberg I, Ben Neriah Z, Kieselstein-Gross E, Mitrani-Rosenbaum S. Kulawa rashin kasawar cututtuka na hyperactivity a ƙananan melanocortin-4-receptor (MC4R) batutuwa marasa galihu. Am J Med Genet B Neuropsychiatr Genet. 2008.147B (8): 1547-1553. [PubMed]
51. Day JJ, Roitman MF, Wightman RM, Carelli RM. Ilimi na ƙwararraji yana jaddada tsauraran matakan canzawa na dopamine a cikin ƙananan ƙwayoyin cuta. Nat Neurosci. 2007.10(8): 1020-1028. [PubMed]
52. Barkley RA. Matasa masu fama da rashin tausayi / rashin tausayi. J likita Pract. 2004.10(1): 39-56. [PubMed]
53. Volkow ND, Wang GJ, Fowler JS, et al. Shaidun cewa methylphenidate yana inganta ƙwarewar aiki ta ilimin lissafi ta hanyar ƙara dopamine cikin kwakwalwar mutum. Am J Zuciyar. 2004.161(7): 1173-1180. [PubMed]
54. Gjedde A, Wong DF, Rosa-Neto P, Cumming P. Mapping neuroreceptors a wurin aiki: a kan fassarar da fassarar bayanan bayan bayan 20 shekaru ci gaba. Int Rev Neurobiol. 2005.63: 1-20. [PubMed]
55. Gatley SJ, Volkow ND, Fowler JS, Dewey SL, Logan J. Sensitivity na [11C] cocaine daura don ragewa a synaptic dopamine. Synapse. 1995.20 (2): 137-144. [PubMed]
56. Zahniser NR, Doolen S. Chronic da kuma nagartaccen tsarin Na + / Cl masu dogara masu kwadago na neurotransmitter. Pharmacol Ther. 2001.92(1): 21-55. [PubMed]
57. Winstanley CA, Eagle DM, Robbins TW. Abubuwan haɗakarwa ta haɓakawa dangane da ADHD: fassarar tsakanin nazarin asibitoci da ƙaddamarwa. Clin Psychol Rev. 2006.26(4): 379-395. [PMC free article] [PubMed]